Navigation Links
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
Date:4/8/2009

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources

WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon Kayaku) to treat the indication.

The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avastin as a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22 percent annual growth from 2012 to 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although market growth will be robust from 2012 to 2017, drug development in recent years in small-cell lung cancer has, overall, been very disappointing. Recent clinical trials have largely eliminated Pfizer's Camptosar/Campto (Daiichi Sankyo's Topotecin), Eli Lilly's Alimta, and GlaxoSmithKline/Nippon Kayaku's Hycamtin from potential first-line status in the indication. Furthermore, despite the impressive sales that Avastin and amrubicin will add to the market, these therapies will have only niche roles in small-cell lung cancer treatment.

"Avastin and amrubicin will each garner only a limited share of the total small-cell lung cancer patient population," said Decision Resources Analyst Janie Mackay, Ph.D. "However, their high price points in an increasingly generic market, mean that those patient shares will translate into substantial market shares."

Despite the disappointing drug development environment, the recent designation of small-cell lung cancer as an orphan disease -- owing to reduced growth rates of the indication -- may help drive future drug development. In the United States, a drug approved to treat an orphan disease receives seven years' market exclusivity and in Europe orphan drugs generally receive 10 years' marketing exclusivity.

"If a drug developer were to produce a novel efficacious agent for small-cell lung cancer, they would benefit from the financial advantages that orphan-drug designation offers in the world's major pharmaceutical markets," Dr. Mackay said.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

          All company, brand, or product names contained in this
        document may be trademarks or registered trademarks of their
                       respective holders.



    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563
    ccomfort@dresources.com       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Bernard R. ... Past President of the American Orthopaedic Society of Sports Medicine (AOSSM) , received ... during the AOSSM Annual Meeting in Toronto, Canada. This prestigious award is given annually ...
(Date:7/21/2017)... , ... July 21, 2017 , ... “Kids aren't born ... to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company ... which launches on Kickstarter on Monday, July 21st. , The kit uses colorful, ...
(Date:7/21/2017)... ... July 21, 2017 , ... How ... are on the rise, say researchers presenting their work at the American ... , “The combination of evaluating the patterns of change in concussion symptom presentation, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, ... pleased to announce their expansion to the Midwest with the establishment of the ... and Ronald Bell, and of counsels, John Peck and Robert Bruns, will establish ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar ... non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has ... to complete regulatory submissions and fund final engineering and initial production of the ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
(Date:6/30/2017)... June 30, 2017  AVACEN Medical (AVACEN) announced the publication of ... describes the use of its AVACEN Treatment Method to ... fibromyalgia. ... AVACEN Medical ... chronic widespread pain. It affects approximately 200 to 400 million people worldwide ...
Breaking Medicine Technology: